LATEST
Janel agreed to acquire EnCor BiotechnologynewNightfood Holdings acquired Jun Long Machine IndustrialnewClimb Global Solutions acquired NeoVADnewValor Energy agreed to acquire Glorious StarOakley Capital / Global Loan Agency ServicesTA Associates / MedEnvision: majority stakeLSEG agreed to acquire OctusStord / AMS Fulfillment: investmentCencora agreed to acquire American Oncology NetworkAPEX / KoraiSmith & Wesson Brands agreed to acquire Long Range IntermediateBose acquired Skullcandy
Open App
ClosedPublished 26 Sep 2022

Emergent /
Chimerix, Inc.

Emergent completes deal with Chimerix, Inc. for TEMBEXA rights

Price
$238m
Stage
Closed
Source · 26 Sep 2022
See the source
01 / BuyerEmergent
02 / TargetChimerix, Inc.
01

What happened

Emergent completed its acquisition of exclusive worldwide rights to TEMBEXA from Chimerix, Inc., including related assets. TEMBEXA is a medical countermeasure for smallpox approved by the U.S. Food and Drug Administration in June 2021.

Emergent paid $238 million, exclusive of customary closing adjustments.

02

The source

Everything on this page comes from the source below.

01
Source · Source

Emergent completes deal with Chimerix, Inc. for TEMBEXA rights

This document is the source for the companies, stage, figure and people on this page.

Original filingUnlock with Pro
03

Timeline

Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.

  1. Also stated

    The source this page is built from.

  2. Published by the source

    The source this page is built from.

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Request accessAlready invited? Sign in

Carrywatch Pro is by invitation. An invite lets you buy Pro.